Study S002271

Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With Obesity

ClinicalTrials.gov record

Registration

Registration: NCT06131437
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 809
Start: 2023-11-27
Primary completion: 2025-12-08
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity
Interventions: DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1292-4835

Registered primary outcomes

To confirm non-inferiority of CagriSema versus tirzepatide: Relative change in body weight [From baseline (week 0) to end of treatment (week 84)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.